<DOC>
	<DOCNO>NCT01621269</DOCNO>
	<brief_summary>Study evaluate efficacy fingolimod patient neutralize antibody 12 month</brief_summary>
	<brief_title>ENGYNE Exploring Gilenya Patients With Neutralizing Antibodies Against Interferon</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Male female subject age 1865 year Subjects relapse remit MS define 2010 revise McDonald criterion Patients Expanded Disability Status Scale ( EDSS ) score 06.5 Interferonbeta ( IFNβ ) treatment least 18 month . Positive IFNNAb titer screen within 6 month prior screen Patients disease activity despite treatment IFNß measure gadoliniumenhancing lesion T1weighted image MRI use tripledose gadolinium protocol and/or new newly enlarge T2 lesion ( T2 lesion : compare reference MRI perform within last 18 month ) patient previous current disease immune system active infection cardiovascular risk patient Patients unable undergo MRI scan , include claustrophobia history hypersensitivity gadoliniumDTPA Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Gilenya</keyword>
	<keyword>Neutralizing Antibodies</keyword>
	<keyword>NAb</keyword>
</DOC>